InvestorWire NewsRoom


RYAH Group Inc. Well Positioned as Data Continues to Shape Future of Medical Research
February 8, 2021

RYAH Group Inc. Well Positioned as Data Continues to Shape Future of Medical Research

  • Recent article finds that data remains one of main drivers of medical research in 2021.
  • New technologies employing AI powered by big data provide new solutions for tackling health problems, expand possibilities of clinical research
  • RYAH combines power of devices combined with data to impact future of medical research to advance treatment of various medical conditions

A recent Becker’s Hospital Review article cites 10 emerging trends in health IT that will shape this field in 2021, reporting that big data management is becoming a need as the use of artificial intelligence (“AI”) and machine learning in healthcare continues to blossom ( With the increasing demand in the medical space for application of analytics powered by novel technology, RYAH Group is set to benefit as a leading digital health care analytics and technology company committed to advancing the world’s transition to remote-health solutions and data analytics in patient treatments.

With the digitalization of medical records and improved medical analytics coupled with a proliferation of wearables, there has been an explosion of medical data over the past decade. That explosion has led to a revolution in medical and health-care research. The vast amount of data available for analysis enables AI-powered algorithms to transform the medical field more than ever before, helping to define what is healthy and to diagnose, treat and prevent any deviations from the ideal standard. The applications go beyond the individual level, offering solutions to tackle health challenges at the level of humanity.

Blossoming of artificial intelligence and machine learning in health care, driven by a combination of wearables and other biomedical devices, will continue to transform clinical research and treatment protocols as well as increase the virtual-care capabilities of health providers, the article observes. “AI is not new in healthcare,” the article notes. “But in the last year AI became crucial in developing predictive models for COVID-19 cases spreading across the country. . . . The field will continue to evolve and become more integrated with clinical care in the coming years.”

Technological advancements make these developments possible as the data continue to be the major trend shaping medical research. The article reports that big data management becomes mission critical as the pandemic highlighted the need for centralized and efficient data management. The data-gathering and reporting efforts accelerated during the virus outbreak, propelling organizations of all sizes to consider cloud implementations to securely store and coordinate data as secure medical research becomes a priority.

As a company committed to leveraging the value of health devices combined with data to positively impact the future treatment of patients with various medical conditions, RYAH is set to be at the forefront of the data-driven medical future. Indispensable in modern medical research, data is at the core of the company’s strategic approach.

RYAH aggregates data collected by its product ecosystem, creating a HIPAA-compliant database enhanced by AI-powered solutions designed to analyze and clarify complex relationships between peer-reviewed research, consumer feedback and therapeutic plants. As the company specializing in unlocking data in the complete therapeutic plant lifecycle – from seed to consumption – RYAH appears strategically placed in the $100.3 billion medical plant market, with the potential to capitalize on growth opportunities enabled by both the IoT and data intelligence (

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).